Language

Pediatric Endocrinology

Pediatric Endocrinology - Research

Gad B. Kletter, MD is a board-certified endocrinologist specializing in the diagnosis and treatment of the endocrine system and hormone disorders in infants, children and adolescents. His clinical areas of interest are in early and delayed onset puberty-related disorders. He treats adrenal disorders, constitutional growth delay, thyroid disorders and short stature.

With over thirty years of experience in pediatric endocrinology, Dr. Kletter comes with national and international respect from his peers and is a leading researcher in his field.  Dr. Kletter conducts various patient research studies to advance treatment and is published in numerous professional articles.

Other areas of focus Dr. Kletter provides include:

  • Precocious puberty
  • Calcium and Phosphorous disorders
  • Hypoglycemia and Hyperlipidemia
  • Pituitary disorders

If you are interested in hearing more or would like to schedule time to discuss research opportunities with him, please call to make an appointment at one of his locations:

Mary Bridge Pediatric Specialty Clinic - Covington:

Phone: 253-403-7296

Mary Bridge Children's Health Center - Tacoma

Phone:  253-403-7296


Do you have a family Member with type 1 diabetes?

The MultiCare Institute for Research & Innovation (MIRI) is partnering with TrialNet to offer risk screening, free of charge, to relatives of people with type I diabetes (T1D). With a simple blood test, TrialNet looks for autoantibodies that can predict risk of developing the disease, and identify the early stages of T1D, sometimes years before symptoms appear. Risk screening also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.

Who can be screened?

• Anyone between the ages of 1 and 45 with a sibling, child or parent with type 1 diabetes.

• Anyone between the ages of 1 and 20 with a sibling, child, parent, cousin, uncle, aunt, niece, nephew, grandparent or half-sibling with type 1 diabetes.

What is risk screening?

A free blood test can identify five autoantibodies that signal an increased risk of type 1 diabetes (T1D). These autoantibodies may show up years before symptoms appear.

• Family members of those with type 1 diabetes have a 15 times greater risk of developing the disease.

• TrialNet screening reveals if you are in the early stages of type 1 diabetes.

Be proactive with your health! Sign up for screening today.

253-403-2699

[email protected]

[email protected]


Pediatric Endocrinology Studies Accepting Patients

Type 2 Diabetes 

AWARD-PEDS T2DM

Study Number: H9X-MC-GBGC - A randomized, double-blind study with an open-label extension comparing the effect of once-weekly Dulaglutide with placebo in pediatric patients with Type 2 diabetes mellitus.

Study Info   

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699


CV181375 T2D

Study Number: D1680C00019 - A 24-week, multicenter, randomized, placebo-controlled, double-blind, parallel group, phase 3 trial with a 28-week safety extension period evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in pediatric patients with Type 2 diabetes mellitus who are between 10 and below 18 years of age.

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699


MK-0431A-289

Study Number: A phase 3 multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of MK-0431A XR (a fixed-dose combination table of Sitagliptin and extended-release Metformin) in pediatric patients with Type 2 diabetes mellitus with inadequate glycemic control on Metformin therapy (alone or in combination with insulin).

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699


Takeda

Study Number: SYR-322-309 - A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Alogliptin compared with placebo in pediatric subjects with Type 2 diabetes mellitus.

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699

Growth Hormone

OPKO GHD

Study Number: CP-4-006 - A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in prepubertal children with growth hormone deficiency.

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699 


Pfizer

Study Number: C0311002 - A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN) INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699 


enliGHten

Study Number: ASCENDIS TRANSCON hGH CT-301EXT - A Multicenter, Phase 3, Long-term, Open-label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children with Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial

Study Info

Principal Investigator(s)Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699

Precocious Puberty

Abbvie

Study Number: ABBVIE M16-904 - Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45 mg 6-month formulation in Children with Central Precocious Puberty

Study Info

Principal Investigator(s):  Gad Kletter, MD

Study Coordinator: Sophie Schmitter, [email protected], 253.403.2699